针对阿尔茨海默病的基于目标的药物输送方法 - 最近的更新
Manu Sharma1, Rupa Mazumder1, Swarupanjali Padhi1
1Department of Pharmaceutics, Noida Institute of Engineering and Technology (Pharmacy Institute), Greater Noida, Uttar Pradesh 201306, India.
Current topics in medicinal chemistry
|March 15, 2026
概括
新型阿尔茨海默氏病 (AD) 治疗向蛋白,M1 mAChR和PDE4s. 黄素和白醇等草药药物表现有前途,提供超越目前有限选择的新治疗途径.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
- 自然产品化学 自然产品化学
背景情况:
- 阿尔茨海默氏症 (AD) 是一个主要的全球健康挑战,有效治疗方法有限.
- 目前的AD药物疗法 (AChE抑制剂,NMDA对抗剂) 有显著的副作用和不良的疾病修饰疗效.
- 挑战包括生物可用性差以及现有药物的血脑屏障 (BBB) 透.
研究的目的:
- 审查阿尔茨海默病的新型治疗点,包括Tau蛋白,M1 mAChR和PDE4s.
- 探索这些新目标的行动机制在AD.
- 讨论对这些目标起作用的合成和草药药物.
主要方法:
- 关于AD治疗的最新研究的文献综述.
- 对新型药物点及其机制的分析.
- 对用于AD治疗的合成和天然化合物的检查.
主要成果:
- 陶蛋白,M1 mAChR和PDE4s是AD治疗的有前途的新目标.
- M1 mAChR调节剂 (激动剂,全化合物,PAMs) 显示出治疗潜力.
- 植物化合物,如帕克利塔克塞尔,黄素,黄素,黄素和素,表现出抗老年痴呆的特性,并准新的途径.
结论:
- 针对Tau,M1 mAChR和PDE4s的新型治疗策略为AD治疗提供了更好的前景.
- 自然产品,特别是PDE4D抑制,是AD药物开发的有希望的途径.
- 对这些目标和化合物的进一步研究可能会导致更有效,更安全的AD疗法.
更多相关视频
08:01Intracerebroventricular Injection of Amyloid-β Peptides in Normal Mice to Acutely Induce Alzheimer-like Cognitive Deficits
Published on: March 16, 2016
44.9K
08:27Establishment of a Valuable Mimic of Alzheimer's Disease in Rat Animal Model by Intracerebroventricular Injection of Composited Amyloid Beta Protein
Published on: July 29, 2018
12.7K
相关概念视频
01:22Alzheimer's Disease: Treatment
1.1K
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.1K
01:26Alzheimer's Disease: Overview
1.9K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.9K
01:24Modified-Release Drug Delivery Systems: Site-Targeted
71
Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
71
01:26Targets for Drug Action: Overview
11.0K
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
11.0K
01:24Site-Targeted Drug Delivery Systems: Polymeric Carriers
82
Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...
82
01:30Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
804
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
804